Literature DB >> 1323143

Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg.

D J Lenschow1, Y Zeng, J R Thistlethwaite, A Montag, W Brady, M G Gibson, P S Linsley, J A Bluestone.   

Abstract

Antigen-specific T cell activation depends on T cell receptor-ligand interaction and costimulatory signals generated when accessory molecules bind to their ligands, such as CD28 to the B7 (also called BB1) molecule. A soluble fusion protein of human CTLA-4 (a protein homologous to CD28) and the immunoglobulin (lg) G1 Fc region (CTLA4lg) binds to human and murine B7 with high avidity and blocks T cell activation in vitro. CTLA4lg therapy blocked human pancreatic islet rejection in mice by directly affecting T cell recognition of B7+ antigen-presenting cells. In addition, CTLA4lg induced long-term, donor-specific tolerance, which may have applications to human organ transplantation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323143     DOI: 10.1126/science.1323143

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  232 in total

1.  Requirement for natural killer T (NKT) cells in the induction of allograft tolerance.

Authors:  K I Seino; K Fukao; K Muramoto; K Yanagisawa; Y Takada; S Kakuta; Y Iwakura; L Van Kaer; K Takeda; T Nakayama; M Taniguchi; H Bashuda; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-20       Impact factor: 11.205

2.  Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2.

Authors:  Y Furukawa; D A Mandelbrot; P Libby; A H Sharpe; R N Mitchell
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

3.  Transplantation of primary and reversibly immortalized human liver cells and other gene therapies in acute liver failure and decompensated chronic liver disease.

Authors:  Stephen M Riordan; Roger Williams
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

Review 4.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

5.  Addition of an IL-15 mutant/FCgamma2A antagonist protein protects islet allografts from rejection overriding costimulation blockade.

Authors:  S Ferrari-Lacraz; X X Zheng; Y S Kim; W Maslinski; T B Strom
Journal:  Transplant Proc       Date:  2002-05       Impact factor: 1.066

6.  CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease.

Authors:  K L Neville; M C Dal Canto; J A Bluestone; S D Miller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 7.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

8.  CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Authors:  J R Abrams; M G Lebwohl; C A Guzzo; B V Jegasothy; M T Goldfarb; B S Goffe; A Menter; N J Lowe; G Krueger; M J Brown; R S Weiner; M J Birkhofer; G L Warner; K K Berry; P S Linsley; J G Krueger; H D Ochs; S L Kelley; S Kang
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

9.  The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury.

Authors:  M Takada; A Chandraker; K C Nadeau; M H Sayegh; N L Tilney
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 10.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.